ActivSignal LLC is structured around transforming technology into systems biology proteomics tools. For researchers working in the biotech space, the firm is offering a proprietary technology inexpensively providing novel insights into signaling pathway activation. The firm's lead product is the IPAD assay (Immuno-Paired-Antibody Detection assay): research tool for analyzing the activity of multiple signaling pathways in one reaction. Developed to enable researchers to understand the pathway activation / inhibition profile of cells, activities of multiple signaling pathways are assessed simultaneously in a single well through the measurement of 70 target human proteins for modifications, cleavage and expression. Each pathway is covered by multiple targets: easily scalable to 96-well format; highly sensitive, requiring small amount of sample for assay.
